{"analyses":[{"ciLowerLimit":"0.09","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.25","estimateComment":"Ripretinib: Placebo; based on stratified Cox Proportional Hazards Regression Model using randomization stratification factors \\[prior lines of therapy (3 versus ≥4); ECOG (0 versus 1 or 2)\\]","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"Two-sided P-value","paramType":"Hazard Ratio, log","paramValue":"0.15","statisticalComment":"Strata: prior lines of therapy (3 versus ≥4); ECOG (0 versus 1 or 2)","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.0","upperLimit":"29.9","value":"27.6"},{"groupId":"OG001","lowerLimit":"4.0","upperLimit":"7.3","value":"4.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"44"}],"units":"Participants"}],"description":"PFS was defined as the time interval between the date of randomization and the earliest documented evidence of the first disease progression based on the independent radiologic review or death due to any cause on initially assigned study treatment, whichever comes earlier, assessed at 26, 39, and 52 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ripretinib (150 mg) once daily in 28-day cycles until disease progression by Independent Radiologic Review (IRR) in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior therapies (therapies must include treatment with imatinib, sunitinib, and regorafenib).","id":"OG000","title":"Ripretinib"},{"description":"Placebo once daily in 28-day cycles until disease progression by Independent Radiologic Review (IRR) in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior therapies (therapies must include treatment with imatinib, sunitinib, and regorafenib).","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"From date of randomization to the earliest date of disease progression or death from any cause [through database cutoff 31-May-2019 (up to approximately 15 months)].","title":"Progression-Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Weeks"}